Magenta Therapeutics Inc

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 2015 and is headquartered in Cambridge, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced progress and encouraging early data in its MGTA-117 Phase 1/2 targeted conditioning clinical trial and a prioritization of its operating plan to more narrowly focus its capital allocation on the MGTA-117 targeted conditioning program, the CD45-ADC (antibody-drug con

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today reported financial results for the fourth quarter and full-year ended December 31, 2021, and recent program highlights. “We expect 2022 will be a year of trial execution and value-creating data readouts, and we are particularly pleased to have dosed our first patient in the

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a Cell Therapy Panel Discussion at the 42nd Annual Cowen Healthcare Conference, to be held virtually, on Wednesday, March 9th, 2022 at 9:10 a.m. ET. A live webcast of the panel can be accessed on the Magenta Therapeutics website

Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today highlighted progress across its portfolio of targeted conditioning and stem cell mobilization programs and set out its milestone expectations for both clinical and preclinical data in 2022. These updates will also be discussed during a webcast presentation at the 40th Annual

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following January investor conferences: 40th Annual J.P. Morgan Healthcare Conference, to be held virtually, on Thursday, January 13th, 2022, at 9:45 a.m. ET, immediately followed by a Q&A session B. Riley Virtual Oncolo

Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today highlighted three presentations made at the 2021 American Society of Hematology (ASH) Annual Meeting. Stem Cell Mobilization: ASH Presentation and Clinical Development Plans The data from an investigator-initiated Phase 2 clinical trial in multiple myeloma, presented on Dece

Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting

Chemocentryx

Epizyme

Hutchison China MediTech Ltd.

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

Big Pharma Is Going Holiday Shopping. Who's Next?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today reported financial results for the third quarter ended September 30, 2021, and recent program highlights. “We are pleased with our recent execution across the portfolio as we look to continue to allocate our capital efficiently to our value-creating opportunities,” sai

Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced positive top-line results from an investigator-initiated Phase 2 clinical trial of MGTA-145 stem cell mobilization in multiple myeloma. The data were accepted for a poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, to be held in A

Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company's Chief Medical Officer where he will be responsible for all clinical development and regulatory initiatives. Dr. Humphrey is a medical oncologist with significant leadership experience in drug develop

Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28 at 4:40 p.m. ET. A live webcast of the fireside chat can be accessed on the Magenta Therapeutics website at https://investor.m

Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference

Apple

Caterpillar

Salesforce

Dow Inc

Goldman Sachs

Intel

Johnson & Johnson

JPMorgan Chase & Co

McDonald's

Travelers

UnitedHealth Group

VOXX International Corporation Class A

Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +57.6% YTD with a record high of 22 out of 37 weeks this year in negative conditions above the 40 MG level.

Week 38 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced today that its Investigational New Drug (IND) application for MGTA-117 is active with the U.S. Food and Drug Administration (FDA). The company expects to open the Phase 1/2 clinical trial in Q4 2021 to evaluate its MGTA-117 antibody-drug conjugate (ADC) targeted conditioning

Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences: BTIG Virtual Biotechnology Conference, presentation at 12:00 p.m. ET on Monday, August 9 2021 Wedbush PacGrow Healthcare Virtual Conference, panel: So Let it Be (Re)Written - Updates in Ge

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The FDA is requiring that Magenta develop an additional bioassay to be used in conjunction with the PK/

Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Magenta Therapeutics, Inc. (MGTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging 21% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company's first Chief Commercial Officer. “Caren has a highly sought-after balance of commercial success and hands-on experience, and we welcome her wide-ranging enterprise leadership expertise,” said Jason Gardner, D.Phil., Ch

Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Thomas Beetham as Chief Legal Officer. “We welcome Tom's extensive legal expertise and cross-functional leadership background,” said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. “I look forward to working alongside

Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced additional positive results from a Phase 2 clinical trial of MGTA-145 and plerixafor in patients with multiple myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021. “We are very pleased to see continued favorable re

Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 4:40 p.m. ET. A live webcast of the fireside chat can be accessed on the Magenta Therapeutics website at https://inves

Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside chats at the following investor conferences this month: Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, at 10:40 a.m. ET Oppenheimer Rare & Orphan D

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced positive preliminary results from its Phase 2 clinical trial of MGTA-145 plus plerixafor in patients with multiple myeloma, which were accepted for presentation at the European Hematology Association (EHA) Congress, to be held virtually June 9-17, 2021. Magenta also provide

Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 shares of its common stock to certain institutional investors in a private placement. Magenta anticipates aggregate gross proceeds from the offering will be $86.4 million, before deducting estimated offering expenses payable

Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the first quarter ended March 31, 2021 and recent program highlights. “Magenta continues to make progress across our program portfolio, building momentum towards several key anticipated clinical and data milestones throughout 2021, including the initial

News for Magenta Therapeutics Inc Stock (MGTA)